Zanlan

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zanlan

Quick Facts

Property Description
Active ingredient Cetirizine Hydrochloride
Form Tablet, Oral Solution
Pharmacological class H1-receptor Antagonist (Antihistamine)
General purpose Mitigation of Allergic Symptoms
Origin Synthetic, Piperazine Derivative

Zanlan's Identity: Definition and Pharmacological Classification

Zanlan is a specific pharmaceutical preparation containing the active component, Cetirizine Hydrochloride. It is formally classified as a selective H1-receptor antagonist, which places it within the established second-generation class of antihistamines. This classification reflects a structural refinement over older compounds, resulting in a reduced potential for central nervous system effects.

The active substance, a piperazine derivative, is recognized for its high affinity for peripheral H1 receptors. This development was intended to provide effective anti-allergic activity while minimizing the sedating effects often associated with first-generation agents. The medication is often positioned for broad family use, commonly found in both tablet and liquid oral solution formats.

Composition and General Therapeutic Purpose

Zanlan is a single-ingredient product, deriving its systemic effect solely from Cetirizine Hydrochloride. The various dosage forms are designed for reliable oral administration. For example, the oral solution utilizes an aqueous vehicle tailored for easy delivery, which is a key consideration for younger patient groups.

Its function as a selective H1-receptor antagonist provides targeted relief from general histamine-mediated conditions. The medication acts to reduce symptoms like itching, sneezing, and watery eyes associated with these reactions. By interrupting the key chemical pathway, the medication serves to mitigate the signs of hypersensitivity reactions without addressing the underlying allergic trigger itself.

What side effects are possible with Zanlan?

Possible side effects and safety information

The safety profile of Zanlan (Cetirizine Hydrochloride) is officially documented by government regulatory bodies, detailing adverse reactions by the body systems affected and their frequency of occurrence (based on pooled clinical trial data and post-marketing experience).

Commonly Documented Adverse Reactions

Adverse reactions classified as Common (affecting 1 in 10 to 1 in 100 people) primarily involve the Nervous System and Gastro-intestinal System. These frequently reported effects include somnolence (sleepiness, which may be dose-related), fatigue, dizziness, headache, and dry mouth.

System-Organ Classes and Less Common Effects

Reactions classified as Uncommon or Rare may involve other system-organ classes. Uncommon reports include agitation, paraesthesia (tingling sensation), and skin reactions like pruritus and rash. Rare effects include hypersensitivity reactions, tachycardia, and abnormal hepatic function (which usually resolves upon discontinuation).

Serious Adverse Reactions and Safety Constraints

Very Rare but serious adverse reactions documented in regulatory sources include anaphylactic shock and thrombocytopenia (low platelet count). Furthermore, caution is recommended for patients with predisposing factors for urinary retention or those at risk of convulsions, such as epileptic patients. The concurrent use of alcohol or other Central Nervous System (CNS) depressants may cause additional reductions in alertness.

Population-Specific and Exposure-Related Safety Notes

Official labels detail that the drug's clearance is reduced in patients with renal or hepatic impairment, and this reduced clearance is also noted in older adults. In cases of severe renal impairment, the use is generally not recommended. A specific regulatory note highlights the risk of severe pruritus (itching) upon discontinuation of the medicine after long-term daily use.

Overdose and Emergency Response

Overdose and when to seek help

Documented Overdose Manifestations

The official regulatory profile for Zanlan (Cetirizine Hydrochloride) is predominantly characterized by central nervous system (CNS) effects. The most frequently documented clinical sign of overdose is somnolence (drowsiness). Overdose presentations may also include restlessness, agitation, headache, and tachycardia (fast heart rate). While rare, regulatory sources document potential severe outcomes, including convulsions and the risk of cardiac arrhythmia, reinforcing the seriousness of ingestion beyond recommended limits.

Overdose in pediatric patients may first exhibit paradoxical symptoms such as restlessness and irritability before the onset of drowsiness, a pattern distinct from adult presentations. Due to reduced drug clearance, caution and close monitoring are noted for geriatric patients and individuals with existing renal impairment.

Required Emergency Action and Management

In all cases of suspected overdose, individuals must seek immediate medical attention or contact a Poison Control Center right away. Emergency services must be contacted immediately if severe, life-threatening symptoms, such as collapse, seizure, or trouble breathing, are observed.

Official regulatory information explicitly states that no known specific antidote exists for this medicine. The required management is limited to symptomatic and supportive treatment. Procedural steps, such as gastric lavage shortly after ingestion, may be considered by healthcare providers.

Therapeutic Uses of Zanlan

What Zanlan Treats: Main Uses and Benefits

Zanlan is generally used across symptom-driven clinical presentations to help provide supportive symptomatic relief, assisting patient comfort during periods of acute or recurring discomfort. The medication's role is commonly to help patients during episodes caused by histamine-mediated reactions. The medication is used to relieve symptoms associated with allergies and hives.


The medication is commonly used to help manage conditions characterized by heightened symptoms, including Seasonal Allergic Rhinitis (hay fever), Perennial Allergic Rhinitis (year-round indoor allergies), Allergic Conjunctivitis, and both Acute and Chronic Urticaria (hives).

A key aspect of the medication's therapeutic role is the mitigation of distressing symptoms: “This medication generally provides supportive relief, assisting with easing the discomfort associated with persistent itching and disruptive nasal symptoms.”


Quick Fact: Supportive Management of Allergic Symptoms

Symptom Domain Key Symptom Relieved Clinical Context
Nasal/Respiratory Sneezing, runny nose, nasal itching Seasonal or perennial allergen exposure
Cutaneous (Skin) Pruritus (itching), hives (welts) Acute or chronic urticaria outbreaks
Ocular (Eye) Itchy, watery, and red eyes Symptomatic allergic conjunctivitis

Zanlan provides supportive relief that may help ease the overall symptom burden, assisting with maintaining functional stability in situations where symptoms interfere with daily functioning. This symptomatic assistance is appropriate when discomfort interferes with function, offering support when symptoms become more noticeable.

Regulatory References

  1. NIH MedlinePlus overview of Cetirizine

Eligibility and Restrictions for Use

Eligibility and Contraindications

Official regulatory information defines specific populations that are eligible, restricted, or excluded from using Zanlan (Cetirizine Hydrochloride).


Absolute Contraindications (Do Not Use)

  • Hypersensitivity: Patients with a known allergy to the active ingredient (Cetirizine), any excipients, the related compound hydroxyzine, or any piperazine derivatives must not use this medication.
  • Severe Renal Impairment: Use is contraindicated in patients with end-stage renal disease or severe kidney failure, typically defined by a creatinine clearance below 10 mL/min.

Eligibility and Conditional Use

Population Group Eligibility Status (as per Official Labeling)
Age (Adults, Adolescents) Approved for use in adults and adolescents ge 12 years.
Age (Pediatric) Approved for specific indications in children ge 6 months (e.g., chronic urticaria) and ge 2 years (e.g., seasonal allergic rhinitis). Tablet forms are generally not recommended for children under 6 years.
Renal Impairment Restricted use: Requires dose adjustment in patients with moderate or severe renal impairment (CrCL 10 to 79 mL/min).
Hepatic Impairment No adjustment is needed for solely hepatic impairment, but adjustment is recommended if renal impairment is also present.
Pregnancy/Lactation Conditional use: Use during pregnancy or breastfeeding is generally not recommended unless necessary and should be discussed with a healthcare professional.
Comorbidities Caution is advised for patients with predisposing factors for urinary retention or those at risk of convulsions (e.g., epilepsy).

This structure reflects the legal classification used by global medicine authorities to establish the boundaries of safe and approved drug use.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Zanlan (Cetirizine Hydrochloride) based on potential pharmacodynamic reinforcement and specific pharmacokinetic changes.

Category
Medicinal product categories with documented interactions
Central Nervous System (CNS) Depressants (including sedatives and tranquilizers)
Specific interacting medicines (if explicitly listed)
Theophylline (400 mg once daily dose)
Substances with documented interactions
Alcohol (Ethanol), Food
Mechanistic basis of interactions (only if stated in label)
Pharmacodynamic Interaction (Additive CNS effects); Pharmacokinetic Interaction (Decreased Clearance)
Population-specific interaction notes (if applicable)
Renal Impairment (including severe) requires specific management due to reduced drug clearance and accumulation risk.

Co-administration with alcohol or other CNS depressants may result in additional impairment of CNS performance and a reduction in alertness. The label states that a multiple-dose study with Theophylline resulted in a 16% decrease in the clearance of Zanlan, which is a documented pharmacokinetic interaction. Studies conducted with Ketoconazole, Erythromycin, and Pseudoephedrine reported no clinically significant drug interactions.

Regarding food, regulatory information notes that while food does not affect the overall extent of exposure (AUC), it does delay the time to attain peak concentration and decreases the maximum concentration. The profile also includes the critical constraint that use is typically contraindicated in patients with severe renal impairment due to the drug's high renal excretion and the resulting risk of accumulation.

Mechanism of Action

Zanlan: Mechanism of Action

Zanlan functions as a Positive Allosteric Modulator (PAM) by selectively engaging the GABA-A receptor in the central nervous system (CNS). This molecular interaction enhances the effect of the inhibitory neurotransmitter GABA, causing a conformational change in the receptor complex. The result is an increase in the conductance of the chloride ion ( Cl^-) channel, leading to greater influx of negative ions and subsequent hyperpolarization of the neuron.

This cellular process modifies neuronal excitability by boosting inhibitory signaling across key neural systems, including the limbic system and the Reticular Activating System (RAS). This targeted pathway adjustment initiates the dampening of neural firing. The consequence is a systemic physiological change characterized by reduced motor output and a resulting decrease in the rate of neuronal discharge. This pharmacodynamic activity shifts the baseline state toward increased central nervous system inhibition, contributing to the overall physiological manifestation of the mechanism.

Dosage and Administration Information

How Zanlan (Cetirizine) is Used

Zanlan administration centers on a primary oral route, utilizing the available tablet, oral solution, or chewable tablet dosage forms. The active component is also available for Intravenous (IV) administration in specialized injectable products used for acute treatment settings.

Dosing and Frequency

The medication is typically administered as a single dose once daily for adults and children six years and older, with a standard adult maintenance dose of 10 mg. The total maximum oral dose is 10 mg in a 24-hour period. Younger children, specifically those between two and under six years, often follow a divided-dose schedule, starting at 2.5 mg and not exceeding 5 mg daily, which may be administered as 2.5 mg twice daily. The dosage may be taken with or without food as intake does not alter the extent of drug exposure.

Procedural Adjustments

Dose modification is utilized for specific patient populations. For older adults (over 65) or patients with renal impairment, the starting dose is frequently lowered to 5 mg once daily to account for physiological changes affecting drug clearance. For moderate to severe renal impairment, the dose may be further reduced to 5 mg every two days as necessary. Usage patterns range from long-term management of chronic conditions to as-needed (PRN) use for acute episodes.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Zanlan

Research for Zanlan (Cetirizine Hydrochloride) includes formal clinical investigations, which often explore comparisons against placebo or other compounds. The resulting evidence describes patterns observed in groups of patients with allergic conditions. This summary will outline what types of studies were conducted and what they examined.


Evidence for Use in Seasonal Allergic Rhinitis (SAR)

Research exploring how symptoms change over time during seasonal allergy periods is well-documented, consisting largely of short-term Randomized Controlled Trials (RCTs) and formal meta-analyses. These studies monitored patient-reported outcomes describing perceived discomfort. Researchers examined the measurement of changes in typical allergy symptoms using standardized tools, such as the Total Symptom Score (TSS) and the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ). The findings describe patterns observed in the studies over the short follow-up periods, usually up to four weeks.


Evidence for Use in Perennial Allergic Rhinitis (PAR)

For year-round allergic rhinitis, research was conducted to explore the management of conditions where symptoms may vary in intensity over many months. These studies were structured as RCTs and featured intermediate to longer observation periods. They focused on outcomes related to systemic or functional imbalance and used Quality of Life (QoL) measures as a key indicator. The research describes how symptoms evolved in the observed populations over defined time intervals. Long-term outcomes extending beyond these specific trial durations are not fully established.


Evidence in Special Populations: Children and Older Adults

Research was conducted to evaluate Zanlan in populations where physiological factors may differ, including children and older adults. For children, studies were conducted during periods of increased symptom activity, observing responses over defined time intervals. Studies explored allergic rhinitis in children beginning at age 2, and chronic urticaria in children beginning at 6 months. Specific research exploring short-term symptom changes in older adults has also been conducted. Data for certain complex conditions remain insufficient, and research is ongoing in these specialized areas.

Key Studies & References

  1. Cetirizine: MedlinePlus Drug Information

Frequently Asked Questions (FAQ)

Common questions about Zanlan (FAQ)


Q: How quickly should I expect Zanlan to start working?

Official product information indicates that the drug is rapidly absorbed, with the maximum concentration in the blood reached in about one hour. This time frame is generally associated with the onset of the drug’s effects. The antihistaminic activity is then noted to persist for at least 24 hours.

Q: What happens if I stop taking Zanlan suddenly?

Official documents note that for patients who use this medication daily for a long period, there is a rare risk of experiencing severe itching (pruritus) following discontinuation of the medicine. This symptom has been documented to appear within a few days after the last dose. This information is based on drug safety communications from regulatory sources.

Q: Is Zanlan a controlled substance or addictive?

Regulatory agencies like the U.S. Drug Enforcement Administration (DEA) have determined that the active ingredient in Zanlan is not classified as a controlled substance. Therefore, the drug does not fall under regulations related to controlled medications.

Q: Are there any common supplements that interact with Zanlan?

The official label does not list specific supplements, but it does include warnings about concurrent use with alcohol or any other central nervous system (CNS) depressants. These substances may increase drowsiness or reduce alertness.

Q: What is the difference between Zanlan and [similar drug X]?

According to its pharmacological classification, Zanlan is a second-generation H1-receptor antagonist, placing it in the modern class of antihistamines. Official documents describe the drug by its classification and mechanism, and do not include comparisons to other specific medicines.

Q: Has Zanlan been studied for long-term use?

Research on the drug includes studies with intermediate-to-longer observation periods. For example, a 35-day study conducted in children observed no evidence of tolerance developing to the antihistaminic effect over that time. Overall, long-term outcomes extending beyond those specific trial durations are not fully described in regulatory summaries.

Q: Do I need to change my diet while taking Zanlan?

Official prescribing information indicates that food intake does not change the total amount of medicine (AUC) that the body ultimately absorbs. While food may slightly delay the time it takes for the drug to reach its peak concentration, regulatory information does not indicate a required change in diet.

Q: Does Zanlan affect blood pressure or heart rate?

Official safety information states that tachycardia (an increase in heart rate) has been reported rarely as a side effect following the drug's approval. The regulatory documents do not provide consistent information about the drug affecting blood pressure.

Q: How long does Zanlan stay in your system after taking it?

The amount of time the drug remains in the body is measured by its half-life, which is the time it takes for half of the drug to be eliminated. In adults, the mean elimination half-life is approximately 8.3 hours.

Q: Is Zanlan available as a generic version?

Yes, the active ingredient in Zanlan, Cetirizine Hydrochloride, is widely available as a generic drug. Regulatory approval for generic versions is handled by agencies such as the FDA.

Q: Are there any foods or drinks that should be avoided with Zanlan?

The official warnings advise against the concurrent use of alcoholic drinks. This is due to the potential for alcohol to increase the risk of drowsiness and reduced alertness, which are also side effects of the drug.

Q: Is Zanlan considered a 'first-line' treatment for its main condition?

International guidelines generally categorize second-generation H1-antihistamines as first-line therapy for common allergic conditions like mild allergic rhinitis and chronic hives. This reflects its established role in managing these conditions.

Q: Can Zanlan be taken with herbal remedies like St. John's Wort?

The official label advises caution or avoidance with any substances classified as CNS depressants. Therefore, the use of herbal remedies, particularly those with known effects on the central nervous system, is a matter where clarification should be sought regarding concurrent use.

Q: Does Zanlan lose effectiveness over time (tolerance)?

Regulatory summaries of clinical studies indicate that no evidence of tolerance (a loss of effectiveness over time) was observed during short-term trials. For example, a study lasting 35 days observed no decrease in the drug's antihistaminic effect.

Q: Is there a patient information leaflet available for Zanlan?

Yes, regulatory agencies mandate that all approved drug products must be accompanied by an official document, often called a Patient Information Leaflet or Drug Facts Label. This document provides standardized, factual information for patients.

Q: How is Zanlan eliminated from the body?

The active component is primarily eliminated from the body through the kidneys (renal excretion). Official information indicates that approximately 50% of the drug leaves the body in the urine as the unchanged substance.

Q: Can Zanlan be crushed or split?

Official instructions regarding the dosage form are provided on the label and should be followed. For example, the regulatory label for the chewable tablet dosage form explicitly states that it is described as being available to be chewed or crushed completely prior to swallowing. Information specific to other dosage forms is available on their respective official labels.

Q: What information is legally required to be provided to patients about Zanlan?

Regulatory agencies, such as the FDA, legally require all over-the-counter (OTC) drug products to include a standardized Drug Facts Label. This label must detail essential information, including active ingredients, specific warnings, side effects, and directions for use.

How should Zanlan be stored and disposed of?

Official Storage and Disposal Requirements

Official regulatory documentation outlines specific requirements for storing and disposing of Zanlan (Cetirizine Hydrochloride) to maintain product quality and safety.

Storage Constraints

Condition Regulatory Requirement
Temperature Store at controlled room temperature, typically between 20 C and 25 C.
Protection Keep the medicine protected from excessive heat, moisture, and direct sunlight.
Container Maintain the product in its original, protective packaging.
Accessibility All medicine must be kept out of the reach of children and pets.

Disposal Rules

No special disposal considerations are required for this product. The preferred method for disposal of unused or expired Zanlan is through an authorized drug take-back program. If a take-back program is unavailable, non-hazardous home disposal involves mixing the medicine with an undesirable substance, such as used coffee grounds or dirt, placing the mixture in a sealed container, and discarding it in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Zanlan found in:

A-Z Index: